• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cencora Inc.

    1/22/26 3:54:36 PM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    DEFA14A 1 tm2533044d2_defa14a.htm DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials
      
    ¨ Soliciting Material Pursuant to §240.14a-12

     

    Cencora, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    xNo fee required.
      
    ¨ Fee paid previously with preliminary materials.
      
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

     

     

     

     

    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V83055-P40517-Z91478 *Please check the meeting materials for any special requirements for virtual meeting attendance. You will need to have the control number above to vote online during the virtual meeting. CENCORA, INC. ATTN: CORPORATE SECRETARY 1 WEST FIRST AVENUE CONSHOHOCKEN, PA 19428 CENCORA, INC. 2026 Annual Meeting of Shareholders Vote by March 4, 2026 11:59 p.m., Eastern Time or during the Annual Meeting on March 5, 2026 3:30 p.m., Eastern Time For shares held in a plan, vote by March 2, 2026 11:59 p.m., Eastern Time You invested in CENCORA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held virtually on March 5, 2026. Vote Virtually during the Meeting* March 5, 2026 3:30 p.m., Eastern Time Virtually at: www.virtualshareholdermeeting.com/COR2026 Get informed before you vote View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting them on or before February 19, 2026. If you would like to request a paper or email copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. There is no charge to you for requesting a paper or email copy. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V83056-P40517-Z91478 THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials at www.ProxyVote.com or easily request a paper or email copy. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote on these important matters. 1. Election of eleven directors. Nominees: 1a. Werner Baumann For 1b. Frank K. Clyburn For 1c. Ellen G. Cooper For 1d. D. Mark Durcan For 1e. Lon R. Greenberg For 1f. Lorence H. Kim, M.D. For 1g. Robert P. Mauch For 1h. Redonda G. Miller, M.D. For 1i. Dennis M. Nally For 1j. Lori J. Ryerkerk For 1k. Lauren M. Tyler For 2. Advisory vote to approve the fiscal 2025 compensation of Cencora, Inc.’s named executive officers. For 3. Ratify the appointment of Ernst & Young LLP as Cencora, Inc.’s independent registered public accounting firm for fiscal 2026. For NOTE: In their discretion, the proxy holders may vote on such other business as may properly come before the meeting or any adjournment, postponement or continuation thereof.

    Get the next $COR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    1/29/2026$400.00Equal-Weight → Overweight
    Morgan Stanley
    1/22/2026$440.00Hold → Buy
    Jefferies
    12/9/2025$400.00Overweight
    Barclays
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    More analyst ratings

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call v

    4/1/26 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina Business

    Cencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of EyeSouth Partners will join Cencora's Retina Consultants of America ("RCA"), a leading management services organization (MSO). "Driven by a commitment to empower ophthalmologists, EyeSouth Partners has built a strong regional network of physicians that provides high quality patient care," said Robert P. Mauch, President and Chief Executive Officer of Cencora. "By joining RCA, these physicians will become part of an organization

    3/23/26 7:00:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Financial Leadership Transition

    Cencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cencora's CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a de

    3/17/26 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cencora upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Cencora from Equal-Weight to Overweight and set a new price target of $400.00

    1/29/26 6:57:57 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora upgraded by Jefferies with a new price target

    Jefferies upgraded Cencora from Hold to Buy and set a new price target of $440.00

    1/22/26 8:20:03 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Barclays initiated coverage on Cencora with a new price target

    Barclays initiated coverage of Cencora with a rating of Overweight and set a new price target of $400.00

    12/9/25 8:43:35 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cencora Inc.

    SC 13D/A - Cencora, Inc. (0001140859) (Subject)

    8/5/24 6:43:49 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

    SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

    7/12/21 8:29:18 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Krikorian Lazarus

    4 - Cencora, Inc. (0001140859) (Issuer)

    4/2/26 4:45:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Executive Vice President Battaglia Silvana converted options into 8,415 shares and covered exercise/tax liability with 3,673 shares, increasing direct ownership by 25% to 23,566 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    3/13/26 4:17:14 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Executive Vice President Campbell Elizabeth S converted options into 12,623 shares and covered exercise/tax liability with 5,842 shares, increasing direct ownership by 28% to 30,706 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    3/13/26 4:16:10 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cencora Inc.

    SCHEDULE 13G/A - Cencora, Inc. (0001140859) (Subject)

    3/26/26 5:13:32 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    3/23/26 7:30:27 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    3/17/26 8:45:16 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Financials

    Live finance-specific insights

    View All

    Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call v

    4/1/26 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Reports Fiscal 2026 First Quarter Results

    Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08 Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5% Adjusted Diluted EPS Guidance Range Reaffirmed at $17.45 to $17.75 for Fiscal 2026 Company Completes Acquisition of OneOncology Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in th

    2/4/26 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access t

    1/6/26 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    5/29/24 4:02:27 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Leadership Updates

    Live Leadership Updates

    View All

    Cencora Announces Financial Leadership Transition

    Cencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cencora's CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a de

    3/17/26 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

    Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora's Chairman since 2016 and previously served as Cencora's Chief Executive Officer from 2011 until 2024. As previously disclosed, Mr. Collis was elected to serve as Executive Chairman of the Board effective October 1, 2024 for a period of one year. "Our Board is confident that Mark's public company CEO and board experience, along with his strategic planning and technological innovation experience, make him the right person to step into t

    8/27/25 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Expands Enterprise Leadership Team with Two Senior Appointments

    Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

    11/4/24 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care